サンプル依頼リスト カート
  • English
  • Korean
表紙：膵外分泌機能不全（EPI）治療および診断の世界市場レポート 2024年
市場調査レポート
商品コード
1415739

膵外分泌機能不全（EPI）治療および診断の世界市場レポート 2024年

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
膵外分泌機能不全（EPI）治療および診断の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

膵外分泌機能不全（EPI）治療および診断市場規模は近年力強く成長しています。2023年の52億4,000万米ドルから2024年には56億9,000万米ドルへとCAGR8.7％で拡大します。この期間の成長は、基礎疾患の有病率の増加、診断ツールの進歩、医薬品の開発、世界のヘルスケアへのアクセスの増加に起因しています。

膵外分泌機能不全（EPI）治療および診断市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.7％で76億7,000万米ドルに成長します。予測期間の成長は、遠隔医療と遠隔モニタリング、データ分析とai、患者教育とサポート、規制変更と償還政策に起因します。予測期間の主な動向には、個別化治療アプローチ、新規治療法の開発、低侵襲診断、共同ケアモデルなどがあります。

糖尿病患者の急増は、当面の膵外分泌機能不全（EPI）治療および診断市場の拡大を促進すると予測されます。糖尿病は、インスリンの分泌不足またはインスリンの使用効率の低下により、血糖値の上昇（高血糖）が長期化する代謝性疾患です。膵酵素補充療法（PERT）を含むEPI治療は、糖尿病とEPIの両方の患者にとって、栄養吸収を高める上で有益であることが証明されています。さらに、糖尿病患者の血糖コントロール改善にも役立ちます。例えば、2021年11月現在、ベルギーに本部を置く230以上の国の糖尿病協会の集合体である国際糖尿病連合は、2021年には推定5億3700万人の成人（20～79歳）が糖尿病に罹患していると報告しています。さらに、糖尿病と闘う人の総数は、2030年までに6億4300万人、2045年までに7億8300万人にエスカレートすると予測されています。その結果、糖尿病有病率の高まりが膵外分泌機能不全（EPI）治療および診断市場成長の主要な促進要因となっています。

消化器疾患の急増は、当面の膵外分泌機能不全（EPI）治療および診断市場拡大の原動力になると予測されます。消化管疾患には、消化を司る器官を含む消化管に影響を及ぼすさまざまな病状が含まれます。胃腸疾患の管理は、酵素不足を是正し、効果的な栄養消化を促進する膵外分泌機能不全（EPI）治療および診断に大きく依存しています。例えば、2023年6月現在、カナダに本部を置く非営利団体Crohn's and Colitis Canadaは、2023年には322,600人以上のカナダ人が炎症性腸疾患（IBD）を患い、人口の約0.82％を占めると推定しています。IBDの有病率は今後も続くと予測され、2035年には約47万人のカナダ人がIBDに罹患すると予想され、これは人口の約1.1％、つまり国民の約91人に1人が罹患することになります。その結果、消化器疾患の罹患率の上昇が膵外分泌機能不全（EPI）治療および診断市場の成長の原動力になると予想されます。

2023年の膵外分泌機能不全（EPI）治療および診断市場で最大の地域は北米でした。膵外分泌機能不全（EPI）治療および診断レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の膵外分泌機能不全（EPI）治療および診断市場、治療法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 栄養管理
  • 膵臓酵素補充療法（PERT）
  • ライフスタイル改善のアプローチ
  • 世界の膵外分泌機能不全（EPI）治療および診断市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血液検査
  • 磁気共鳴画像法（MRI）
  • 内視鏡超音波検査（EUS）
  • コンピュータ断層撮影（CT）スキャン
  • 世界の膵外分泌機能不全（EPI）治療および診断市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ジェネリック
  • ブランド
  • 世界の膵外分泌機能不全（EPI）治療および診断市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 直接入札
  • 小売薬局
  • サードパーティの販売代理店
  • その他
  • 世界の膵外分泌機能不全（EPI）治療および診断市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • 在宅ケア
  • 診断センター
  • 研究および学術機関
  • その他

第7章 地域および国の分析

  • 世界の膵外分泌機能不全（EPI）治療および診断市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の膵外分泌機能不全（EPI）治療および診断市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 膵外分泌機能不全（EPI）治療および診断市場の競合情勢
  • 膵外分泌機能不全（EPI）治療および診断市場の企業プロファイル
    • Pfizer Inc.
    • Merck &Co. Inc.
    • Janssen Pharmaceuticals Inc.
    • AbbVie Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Sanofi S.A.
  • AstraZeneca plc
  • Abott Laboratories
  • Medtronic plc
  • Solvay S.A.
  • Laboratory Corporation of America Holdings (Labcorp)
  • Organon group of companies Metagenics LLC
  • Allergan plc
  • Chiesi Farmaceutici S.p.A.
  • Codexis Inc.
  • Nordmark Arzneimittel GmbH & Co. KG
  • ChiRhoClin Inc.
  • Digestive Care Inc.
  • Alcresta Therapeutics Inc.
  • Vivus Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12338

“Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
  • 2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
  • 3) By Drug Type: Generic; Branded
  • 4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
  • 5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.24 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The surge in diabetes cases is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Diabetes is a persistent metabolic ailment characterized by prolonged elevated blood sugar levels (hyperglycemia) resulting from either insufficient insulin production or the body's inefficiency in using the insulin it generates. EPI treatment, which encompasses pancreatic enzyme replacement therapy (PERT), proves beneficial in enhancing nutrient absorption for individuals with both diabetes and EPI. Moreover, it aids in bettering glycemic control for those with diabetes. For instance, as of November 2021, the International Diabetes Federation, a Belgium-based conglomerate of over 230 national diabetes associations, reported that an estimated 537 million adults (20-79 years old) were afflicted with diabetes in 2021. Furthermore, the total number of individuals grappling with diabetes is projected to escalate to 643 million by 2030 and 783 million by 2045. Consequently, the mounting prevalence of diabetes is a key driver for the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market's growth.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

The exorbitant cost of treatment is anticipated to hinder the progress of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market throughout the forecast period. High treatment expenses in healthcare refer to the substantial financial outlays associated with medical care, often posing a considerable burden on individuals. The treatment modalities for exocrine pancreatic insufficiency (EPI) encompass nutritional management and pancreatic enzyme replacement therapy (PERT), which can be either generic or branded, leading to moderate to high costs incurred during the treatment process. As an illustration, in January 2021, as reported by the American Society of Clinical Oncology, a US-based professional organization representing physicians across all oncology sub-specialties, the out-of-pocket expenses for a 30-day supply of enzymes for Medicare beneficiaries could reach up to $1000. The lipase content per unit spanned from 3,000 to 40,000 USP units, with a per-unit list price ranging from $1.44 to $13.89. Consequently, the elevated treatment costs served as a significant constraint on the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Prominent companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are dedicated to pioneering innovative studies and solutions, like PACT-CP, to maintain their standing in the industry. For instance, in June 2021, Aimmune Therapeutics, a biopharmaceutical company based in the United States, introduced PACT-CP-a patient-centric chronic pancreatitis registry study. This initiative aims to gain deeper insights into the unmet needs and therapeutic challenges faced by patients dealing with EPI as a consequence of chronic pancreatitis (CP). Notably, it stands as the inaugural real-world registry study designed specifically for individuals with chronic pancreatitis. The study, which will track approximately 400 patients across 20 gastroenterology facilities in the United States, was developed in collaboration with patients and expert advisors. The PACT-CP Registry study constitutes a forward-looking, non-interventional research endeavor tailored for patients undergoing gastroenterology treatment and diagnosed with EPI stemming from chronic pancreatitis.

In September 2021, AzurRx BioPharma, a clinical-stage biopharmaceutical company headquartered in the United States, completed the acquisition of First Wave Bio Inc. for a total of $229 million. This pivotal acquisition has led AzurRx to rebrand as 'First Wave BioPharma Inc.' The strategic move signifies a significant expansion of the company's gastrointestinal (GI) development portfolio, propelling AzurRx into a prominent position in the realm of therapeutic interventions for inflammatory bowel diseases. First Wave Bio Inc., a US-based pharmaceutical entity, specializes in treating exocrine pancreatic insufficiency (EPI) in patients afflicted with cystic fibrosis and chronic pancreatitis.

Major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, Abott Laboratories, Medtronic plc, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan plc, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG .

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Growth

  • 5.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

  • 6.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nutritional Management
  • Pancreatic Enzyme Replacement Therapy (PERT)
  • Lifestyle Modifications Approach
  • 6.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Blood Tests
  • Magnetic Resonance Imaging (MRI)
  • Endoscopic Ultra-Sonography (EUS)
  • Computerized Tomography (CT) Scanning
  • 6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Generic
  • Branded
  • 6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Direct Tender
  • Retail Pharmacy
  • Third-Party Distributor
  • Other Distribution Channels
  • 6.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Diagnostic Centre
  • Research And Academic Institutes
  • Other End Users

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

  • 7.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 9.1. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 9.2. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 10.1. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 11.1. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 11.2. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 12.1. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 13.1. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 14.1. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 14.2. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 15.1. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 15.2. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 16.1. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 17.1. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 18.1. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 19.1. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 20.1. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 21.1. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 21.2. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 22.1. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 23.1. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 23.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 24.1. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 24.2. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 25.1. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 25.2. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 26.1. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 26.2. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 27.1. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 28.1. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 28.2. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 29.1. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 29.2. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape
  • 30.2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Janssen Pharmaceuticals Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. AstraZeneca plc
  • 31.3. Abott Laboratories
  • 31.4. Medtronic plc
  • 31.5. Solvay S.A.
  • 31.6. Laboratory Corporation of America Holdings (Labcorp)
  • 31.7. Organon group of companies Metagenics LLC
  • 31.8. Allergan plc
  • 31.9. Chiesi Farmaceutici S.p.A.
  • 31.10. Codexis Inc.
  • 31.11. Nordmark Arzneimittel GmbH & Co. KG
  • 31.12. ChiRhoClin Inc.
  • 31.13. Digestive Care Inc.
  • 31.14. Alcresta Therapeutics Inc.
  • 31.15. Vivus Inc.

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking

33. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Future Outlook and Potential Analysis

  • 35.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer